The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.
Ages above 18;
Being able to verbally confirm understanding of the trial risks, benefits, and treatment options of receiving treatment with fexofenadine hydrochloride. He/she or his/her legal representative shall provide written informed consent before participating in the clinical trial.
Clinical symptoms: ischemic chest pain lasting for over 30 minites;
Elevated serum cTn: at least once higher than the upper limit of normal values (99th percentile of the reference upper limit);
Long term use of fexofenadine hydrochloride or other H1 receptor inhibitors;
Previously suffered from myocardial infarction or received coronary artery bypass grafting;
Patients with concomitant cardiomyopathy or valve disease;
History of severe renal failure, estimated glomerular filtration rate (eGFR) < 30ml/min;
Parallel
Fexofenadine Hydrochloride
DrugFexofenadine hydrochloride 60mg bid treatment for 6 months on the basis of standard treatment.
Placebo
Other interventionPlacebo administration for 6 months on the basis of standard treatment.
Late gadolinium enhancement/Left ventricular mass (LGE/LV%)
The difference of LGE/LV% from baseline. LGE/LV% will be assessed by CMR.
Left ventricular ejection fraction (LVEF)
The difference of LVEF from baseline. LVEF will be assessed by CMR.
Left ventricular end-systolic volume/body surface area (LVESV/BSA%)
The difference of LVESV/BSA% from baseline. LVESV will be assessed by CMR and BSA will be calculated by height and weight.
Left ventricular end-diastolic volume/body surface area (LVEDV/BSA%)
The difference of LVEDV/BSA% from baseline. LVEDV will be assessed by CMR and BSA will be calculated by height and weight.
Left ventricular ejection fraction (LVEF)
The difference of LVEF from baseline. LVEF will be assessed by UCG.
Click on the lead sponsor to view all of their trials.
